Monographie - Etoposide phosphate - Stabilis 4.0

Viimane versioon :
08/05/2024

Vähiravimite

Etoposide phosphate

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

Stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

Pdf

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Etopofos	Argentiina, Austria, Norra, Rootsi, Soome, Taani
Etopophos	Ameerika ühendriigid, Belgia, Bulgaaria, Holland, Iisrael, Lõuna Aafrika Vabariik, Luksemburg, Poola, Prantsusmaa, Saksamaa, Suurbritannia, Sveits, Uus-Meremaa
Nexvep	Brasiilia
Toposar	Ameerika ühendriigid

Viited

Süsteravim

Viited : Etoposide phosphate

	Tüüp	Avaldamine
1410	Ajaleht	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1411	Ajaleht	Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc 1999 ; 39: 146-150.
1423	Ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1606	Ajaleht	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	Ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Ajaleht	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Ajaleht	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Ajaleht	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3644	Labor	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3655	Labor	Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2016
3838	Labor	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4102	Ajaleht	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.

Mentions Légales